




RealRate

PHARMACEUTICAL 2023

Longboard Pharmaceuticals Inc
Rank 147 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Longboard Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Longboard Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Longboard Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 321%, being 77% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	69,838
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,764
Liabilities, Non-Current	0
Other Assets	769
Other Compr. Net Income	-528
Other Expenses	0
Other Liabilities	0
Other Net Income	853
Other Revenues	0
Property and Equipment	9.0
Research and Development	34,638
Selling, General and Administrative Expense	10,160

Output Variable	Value in 1000 USD
Assets	70,616
Liabilities	8,764
Expenses	44,798
Revenues	0
Stockholders Equity	61,852
Net Income	-43,945
Comprehensive Net Income	-44,209
BaseVar	62,780
ECR before Limited Liability	228%
Economic Capital Ratio	321%